References
- Applebaum F R, Radich J. Acute myeloid leukemia. Hematology 2001; 87–112
- Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569–3576
- Gandhi V, Huang P, Xu Y Z, Heinemann V, Plunkett W. Metabolism and action of 2′,2′-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol A 1991; 309: 125–130
- Huang P, Chubb S, Hertel L W, Grindey G B, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110–6117
- Plunkett W, Huang P, Xu Y Z, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22(4 Suppl 11)3–10
- Grunewald R, Kantarjian H, Keating M J, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823–6826
- Heinemann V, Xu Y Z, Chubb S, Sen A, Hertel L W, Grindey G B, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52: 533–539
- Kano Y, Suzuki K, Akutsu M, Suda K. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 1992; 6: 440–445
- Kano Y, Akutsu M, Tsunoda S, Suzuki K, Ichikawa A, Furukawa Y, et al. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 2000; 14: 379–388
- Tosi P, Pellacani A, Zinzani P L, Magagnoli M, Visani G, Tura S. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999; 84: 794–798
- Shanks R H, Rizzieri D A, Flowers J L, Colvin O M, Adams D J. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res 2005; 11: 4225–4233
- Rizzieri D A, Bass A J, Rosner G L, Gockerman J P, DeCastro C M, Petros W P, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002; 20: 674–679
- Rizzieri D A, Ibom V K, Moore J O, DeCastro C M, Rosner G L, Adams D J, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res 2003; 9: 663–668
- Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, et al. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Res 2003; 27: 301–304
- O'Quigley J, Paoletti X. Continual reassessment method for ordered groups. Biometrics 2003; 59: 430–440
- Piantadosi S, Fisher J D, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 1998; 41: 429–436
- Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
- Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649
- Mayer L D, Harasym T O, Tardi P G, Harasym N L, Shew C R, Johnstone S A, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006; 5: 1854–1863